HC Wainwright set a $2.00 target price on Proteon Therapeutics (NASDAQ:PRTO) in a research report sent to investors on Friday morning. The firm currently has a hold rating on the biopharmaceutical company’s stock.
Several other research firms have also recently weighed in on PRTO. Robert W. Baird set a $3.00 price objective on Proteon Therapeutics and gave the company a hold rating in a report on Wednesday. Zacks Investment Research cut Proteon Therapeutics from a hold rating to a sell rating in a report on Thursday, January 11th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $3.38.
Shares of Proteon Therapeutics (NASDAQ:PRTO) traded up $0.30 on Friday, reaching $2.45. The company’s stock had a trading volume of 90,849 shares, compared to its average volume of 27,368. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $2.85.
Proteon Therapeutics (NASDAQ:PRTO) last issued its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.14. sell-side analysts expect that Proteon Therapeutics will post -1.63 EPS for the current year.
A hedge fund recently raised its stake in Proteon Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,500 shares of the biopharmaceutical company’s stock after purchasing an additional 29,600 shares during the period. Renaissance Technologies LLC owned approximately 1.14% of Proteon Therapeutics worth $383,000 at the end of the most recent quarter. Institutional investors and hedge funds own 50.56% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2018/03/17/proteon-therapeutics-prto-given-a-2-00-price-target-at-hc-wainwright.html.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.